L

Lumos Diagnostics Holdings Ltd
ASX:LDX

Watchlist Manager
Lumos Diagnostics Holdings Ltd
ASX:LDX
Watchlist
Price: 0.031 AUD 3.33% Market Closed
Market Cap: 23.2m AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LDX Price Targets Summary
Lumos Diagnostics Holdings Ltd

There are no price targets for LDX.
LDX Lowest Forecast
Wall Street Target
Not Available
LDX Average Forecast
Wall Street Target
Not Available
LDX Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Lumos Diagnostics Holdings Ltd Competitors:
Price Targets
HAE
Haemonetics Corp
33% Upside
ALGN
Align Technology Inc
28% Upside
7730
Mani Inc
44% Upside
X
XTNT
Xtant Medical Holdings Inc
155% Upside
HAE
Haemonetics Corp
33% Upside
ALGN
Align Technology Inc
28% Upside
7730
Mani Inc
44% Upside
X
XTNT
Xtant Medical Holdings Inc
155% Upside
1066
Shandong Weigao Group Medical Polymer Co Ltd
14% Upside
I
688253
Innovita Biological Technology Co Ltd
25% Upside
4549
Eiken Chemical Co Ltd
16% Upside
LNTH
Lantheus Holdings Inc
62% Upside

Revenue
Forecast

Revenue Estimate
Lumos Diagnostics Holdings Ltd

For the last 5 years the compound annual growth rate for Lumos Diagnostics Holdings Ltd's revenue is 20%. The projected CAGR for the next 3 years is 29%.

20%
Past Growth
29%
Estimated Growth
Estimates Accuracy
-27%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lumos Diagnostics Holdings Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lumos Diagnostics Holdings Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-55%
Average Miss
What are analyst estimates?

See Also

Summary
LDX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LDX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LDX stock valuation using valuation multiples.
Wall Street Estimates
LDX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LDX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LDX's stock price target?
Not Available

LDX doesn't have any price targets made by Wall Street professionals.

What is Lumos Diagnostics Holdings Ltd's Revenue forecast?
Projected CAGR
29%

For the last 5 years the compound annual growth rate for Lumos Diagnostics Holdings Ltd's revenue is 20%. The projected CAGR for the next 3 years is 29%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 260,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.